JP2021505620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505620A5 JP2021505620A5 JP2020531164A JP2020531164A JP2021505620A5 JP 2021505620 A5 JP2021505620 A5 JP 2021505620A5 JP 2020531164 A JP2020531164 A JP 2020531164A JP 2020531164 A JP2020531164 A JP 2020531164A JP 2021505620 A5 JP2021505620 A5 JP 2021505620A5
- Authority
- JP
- Japan
- Prior art keywords
- arginase
- human
- subject
- use according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023199616A JP2024028760A (ja) | 2017-12-05 | 2023-11-27 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762594747P | 2017-12-05 | 2017-12-05 | |
| US62/594,747 | 2017-12-05 | ||
| US201862725612P | 2018-08-31 | 2018-08-31 | |
| US62/725,612 | 2018-08-31 | ||
| US201862745000P | 2018-10-12 | 2018-10-12 | |
| US62/745,000 | 2018-10-12 | ||
| PCT/US2018/063982 WO2019113157A1 (en) | 2017-12-05 | 2018-12-05 | Method and composition for treating arginase 1 deficiency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023199616A Division JP2024028760A (ja) | 2017-12-05 | 2023-11-27 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505620A JP2021505620A (ja) | 2021-02-18 |
| JP2021505620A5 true JP2021505620A5 (https=) | 2022-01-11 |
| JP7827407B2 JP7827407B2 (ja) | 2026-03-10 |
Family
ID=64734275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531164A Active JP7827407B2 (ja) | 2017-12-05 | 2018-12-05 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
| JP2023199616A Pending JP2024028760A (ja) | 2017-12-05 | 2023-11-27 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023199616A Pending JP2024028760A (ja) | 2017-12-05 | 2023-11-27 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11717562B2 (https=) |
| EP (1) | EP3720476A1 (https=) |
| JP (2) | JP7827407B2 (https=) |
| KR (2) | KR20200122298A (https=) |
| CN (3) | CN120661640A (https=) |
| AU (1) | AU2018378485B2 (https=) |
| CA (1) | CA3084801A1 (https=) |
| MX (2) | MX2020005933A (https=) |
| TW (1) | TWI878212B (https=) |
| WO (1) | WO2019113157A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3449935A1 (en) * | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
| CA3116736A1 (en) * | 2018-10-19 | 2020-04-23 | Aerase, Inc. | Arginine depletion therapy for treatment of gamt deficiency |
| CN114729344A (zh) * | 2019-08-30 | 2022-07-08 | 安格利亚生物制药公司 | 人重组精氨酸酶1的生产方法及其用途 |
| CN114214353B (zh) * | 2021-11-30 | 2023-07-18 | 新泰市佳禾生物科技有限公司 | 一种发酵生产人重组精氨酸酶i的方法 |
| CN114196712B (zh) * | 2021-11-30 | 2024-04-02 | 新泰市佳禾生物科技有限公司 | 一种固定化酶法生产l-鸟氨酸的方法 |
| CN114350721B (zh) * | 2021-11-30 | 2024-05-24 | 新泰市佳禾生物科技有限公司 | 微生物酶法生产l-鸟氨酸的方法 |
| CN116179452A (zh) * | 2022-07-11 | 2023-05-30 | 山东第一医科大学(山东省医学科学院) | 一种用于治疗精氨酸酶缺乏症的工程益生菌及其构建方法和应用 |
| WO2025171346A1 (en) * | 2024-02-08 | 2025-08-14 | University Of Florida Research Foundation, Incorporated | Indoleamine 2,3-dioxygenase variants |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02117383A (ja) | 1988-10-26 | 1990-05-01 | Tosoh Corp | ヒトアルギナーゼの製造方法 |
| US5780286A (en) | 1996-03-14 | 1998-07-14 | Smithkline Beecham Corporation | Arginase II |
| EP1499342A2 (en) | 2002-01-25 | 2005-01-26 | Cancer Treatments International | Therapeutic composition for treatment of cancer by arginine depletion |
| HK1053577A2 (en) | 2002-06-20 | 2003-10-10 | Bio-Cancer Treatment International Limited | Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation |
| GB0315248D0 (en) * | 2003-06-30 | 2003-08-06 | Hoffmann La Roche | HCV regulated protein expression |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| CN1745847A (zh) | 2004-09-08 | 2006-03-15 | 康达医药科技有限公司 | 用精氨酸酶治疗肝炎的药物组合物和方法 |
| DE602006019916D1 (de) | 2005-12-12 | 2011-03-10 | Canji Inc | Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase |
| PT3778885T (pt) | 2008-10-31 | 2023-05-31 | Aerase Inc | Composições de arginases humanas modificadas e métodos para o tratamento do cancro |
| US9382525B2 (en) | 2009-03-26 | 2016-07-05 | The Hong Kong Polytechnic University | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents |
| CA2766039A1 (en) | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
| WO2012061015A2 (en) | 2010-11-03 | 2012-05-10 | Scott & White Healthcare | L-citrulline supplementation during arginine depletion therapy with arginase |
| CN103184209B (zh) * | 2011-12-27 | 2015-09-16 | 拜奥生物科技（上海）有限公司 | 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用 |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| EP4063503A1 (en) | 2014-02-11 | 2022-09-28 | The Regents of the University of Colorado, a body corporate | Crispr enabled multiplexed genome engineering |
| CA2944903A1 (en) | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| ES2897635T3 (es) * | 2014-04-29 | 2022-03-02 | Bio Cancer Treat International Ltd | Métodos y composiciones para modular el sistema inmunológico con la arginasa I |
| EP2982758A1 (en) | 2014-08-04 | 2016-02-10 | Centre Hospitalier Universitaire Vaudois (CHUV) | Genome editing for the treatment of huntington's disease |
| HRP20190881T1 (hr) | 2014-08-28 | 2019-07-12 | Halozyme, Inc. | Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke |
| US11136597B2 (en) | 2016-02-16 | 2021-10-05 | Yale University | Compositions for enhancing targeted gene editing and methods of use thereof |
| ES2909074T3 (es) * | 2016-05-06 | 2022-05-05 | Phasebio Pharmaceuticals Inc | Proteínas de fusión ELP para liberación controlada y sostenida |
-
2018
- 2018-12-05 US US16/210,248 patent/US11717562B2/en active Active
- 2018-12-05 KR KR1020207019283A patent/KR20200122298A/ko not_active Ceased
- 2018-12-05 WO PCT/US2018/063982 patent/WO2019113157A1/en not_active Ceased
- 2018-12-05 TW TW107143773A patent/TWI878212B/zh active
- 2018-12-05 AU AU2018378485A patent/AU2018378485B2/en active Active
- 2018-12-05 KR KR1020267007681A patent/KR20260047622A/ko active Pending
- 2018-12-05 JP JP2020531164A patent/JP7827407B2/ja active Active
- 2018-12-05 CN CN202510809152.4A patent/CN120661640A/zh active Pending
- 2018-12-05 CN CN202510809272.4A patent/CN120643682A/zh active Pending
- 2018-12-05 EP EP18821957.0A patent/EP3720476A1/en active Pending
- 2018-12-05 MX MX2020005933A patent/MX2020005933A/es unknown
- 2018-12-05 CN CN201880079119.9A patent/CN111787941A/zh active Pending
- 2018-12-05 CA CA3084801A patent/CA3084801A1/en active Pending
-
2020
- 2020-07-13 MX MX2025006207A patent/MX2025006207A/es unknown
-
2023
- 2023-06-29 US US18/344,083 patent/US20240009284A1/en active Pending
- 2023-11-27 JP JP2023199616A patent/JP2024028760A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505620A5 (https=) | ||
| JP7038094B2 (ja) | 治療用として改善された特性を有するβ－ラクタマーゼ | |
| ES2587595T3 (es) | Péptidos y polipéptidos de permeabilización celular para células microbianas | |
| TWI634212B (zh) | 用於癌症標靶治療之含有結合白蛋白的精胺酸去亞胺酶之醫藥組成物 | |
| JP2021502980A5 (https=) | ||
| JP2014051497A5 (https=) | ||
| CA3073317A1 (en) | Engineered dnase enzymes and use in therapy | |
| JP2013505270A5 (https=) | ||
| JP2012519489A5 (https=) | ||
| JP2008508859A5 (https=) | ||
| Elsayed et al. | Nephrotoxicity of cefepime: A new cephalosporin antibiotic in rats | |
| JP2010533478A5 (https=) | ||
| Ritchie et al. | Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond | |
| ES2890555T3 (es) | Tripsina de bacalao para uso en el tratamiento de infecciones microbianas en un sujeto con inmunodeficiencia | |
| Keary et al. | Characterization of a bacteriophage-derived murein peptidase for elimination of antibiotic-resistant Staphylococcus aureus | |
| JP2015535237A5 (https=) | ||
| Su et al. | Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance | |
| JP2018500341A5 (https=) | ||
| US12104186B2 (en) | Deimmunized lysostaphin and methods of use | |
| JP2011527317A5 (https=) | ||
| CN110117587A (zh) | 一种葡萄球菌裂解酶及其保存方法和应用 | |
| JP2008512399A5 (https=) | ||
| JP2019513138A5 (https=) | ||
| JP3104257B2 (ja) | 心疾患治療剤 | |
| Besada | Rapid growing mycobacteria and TNF-α blockers: case report of a fatal lung infection with Mycobacterium abscessus |